Neurochem/J&J’s Kiacta Action Date Extended To July 16
This article was originally published in The Pink Sheet Daily
Executive Summary
Canadian firm responded last fall to an “approvable” letter for the Amyloid A amyloidosis treatment and submitted additional information in February.